Pioneering Bioconjugates With Novel Payloads & Targeting Formats

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.

The 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates, join us to delve into each of their value propositions and navigate crucial considerations like target selection, PK/PD profiles, and translation into the clinic.

Connect with 100+ experts from big pharma, cutting-edge biotechs and conjugation and manufacturing providers, all sharing crucial insights on striking success with new formats and payloads.

Now is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!